1

Curriculum vitae Martin F. Bachmann Personal data date of birth: 15. December 1967 birthplace: Winterthur, Switzerland citizen of Winterthur address: Alte Tösstalstr 20 8487 Rämismühle Switzerland marital status: married, two children Education 1974-1980: primary school in Hettlingen (Switzerland) 1980-1986: Gymnasium in the Kantonschule Rychenberg, Winterthur 1986: Eidgenössiche Matura Typus B (final examination) 1986-1991: Study of cell biology at the Eigenössichen Technischen

Hochschule Zürich (ETH). Diploma thesis at the Institute for Neurobiology in the laboratory of Prof. Dr. M. Schachner on the influence of cell adhesion molecules on the adheseviness of the extracellular matrix.

The thesis was honoured with the ETH silver medal. 1991: Completion of studies (Dipl. Natw.ETH). Final examinations were passed with distinction since maximal marks were achieved in all examinations. 1991-1995: PhD thesis in the Institute for Experimental Immunology in the lab of Prof. Zinkernagel and Prof. Hengartner under the supervision of Prof. Zinkernagel (ETH Zürich/Universitätsspital Zürich). The thesis was honoured with the ETH silver medal. Professional Experience 1995: Post-Doc in the lab of Prof. Zinkernagel, Universitätsspital Zürich 1995-1997: Post-Doc in the lab of Prof. Ohashi, OCI, Toronto, Canada 1997-2000: Member at the Basel Institute for Immunology, Basel, Switzerland 2000-2012: Chief Scientific Officer, Cytos Biotechnology AG, Zürich-Schlieren.

Buildup of research group of 40-50 people at Cytos. 2003-2010: Board of directors, Mavena AG 2006-: Scientific Advisory Board of Biotechnology Institute Thurgau 2012-: Scientific Advisory Board of a number of companies 2012: Founding of Saiba GmbH, Areba AG and Hypopet 2012-: Visiting professor at University of Zürich

2

2013-: Professor of Immunology (associate), University of Oxford 2014-2015: Director of research NCCCR/HMC 2015-: Professor of Immunology, Bern Prizes and honours

• ETH Silver Medal for diploma thesis (1991) • Honoured final examinations (maximal marks in all examinations) (1991) • ETH Silver Medal for PhD thesis (1995) • Pfizer Prize 1998 for Immunology • Swiss Technology Award 2004 (Cytos) • Swiss Technology Award 2013 (Hypopet i.G.)

Grants:

• Swiss National Fond and Roche research foundation during Post-Doc in Toronto • KTI research grants 4235.1 KTS, 5748.2 KTS and 110011.2 PFLS-LS • EU-research grants: QLK2-CT-2000–01476, MUGEN, COMPUCAV, TSEUR,

VECTORIE I have not access to the exact number; total is, however> 1 Mio €)

(After 2012, as Cytos was not eligible for most grants):

• Novartis Research Foundation (2012). The role of antibody affinity in mediating protection against autoimmune disease: CHF 60`000 (For finishing the PhD of one of my students; as I was still hired by Cytos, Prof Hennecke was kind enough to be the official representative)

• Roche EIN (2012) (Bispecific anti-tumour antibodies: combining tumour- specificity with cytokine agonism) CHF 300`000

• Oncosuisse (KFS-3111-02-2013) (Bispecific anti-tumour antibodies: combining tumour- specificity with cytokine agonism) CHF 240`000

• SNF (31003A_149925) (2013) (Tracking antigen-specific memory B cell responses at the cellular and molecular level) CHF 484`000

• KTI for collaboration Saiba GmbH and Dr Thomas Kündig: Entwicklung eines

Alzheimer Impfstoffes der nächsten Generation. CHF 126`000

3

• Michael J Fox Foundation (Development of a vaccine against Parkinson`s disease) (2013) $630`000 (Primary investigator; Richard Wade-Martins, Leader of the Oxford Parkinson Center as Co-Investigator)

• Malaria Vaccine Initiative (Development of VLP-based vaccines against malaria) (2013) 150`000£ (Co-Investigator, primary Investigator is Dr Sumi Biswas) Total since 2012: ca. CHF 1.9 Mio.

Drug candidates reaching clinical development from research at Cytos

• CYT-001: Proof-of-Concept for immunogenicity; Phase I completed • CYT-002: Immunodrug for treatment of smoking addiction; Phase I completed,

Phase II reaches proof-of-concept. • CYT-003: Immunodrug for the treatment of allergies; Phase I completed clinical

proof-of-concept for rhinitis has been reached in phase IIa and phase IIb studies • CYT-003: Immunodrug for the treatment of asthma. Clinical proof-of-concept has

been reached in phase IIa study • CYT-005: Immunodrug against house-dust-mite allergy; Phase I completed,

Phase II reaches proof-of-concept. • CYT-006: Immunodrug against hypertension; preclinical research completed;

Proof-of-concept reached in Phase 2a study. Phase IIb study ongoing • CYT-004: Immunodrug against Melanoma; preclinical research completed;

Several phase I/II completed. The drug candidate has been shown to induce good T cell responses

• Immunodrug against Alzheimer`s disease (in collaboration with Novartis); preclinical research completed; several Phase II studies are ongoing

• CYT-0013: Immunodrug against type II diabetes.

4

Teaching Experience: Cytos Biotechnology: Supervision of the following PhD students

i) Completed

• Daniel Koller • Marco Boorsma • Tazio Storni • Patrick Bättig • Andrea Jegerlehner • Christine Piossek • Dominique Gatto (received ETH silver medal for her work) • Juliana Bessa • Caroline von Almen • Susanne Keller • Christina Uermösi • Kiran Dallenbach • Deepa Mohanan • Franziska Zabel

ii) Ongoing

• Florian Olomski • Elisa Rösti • Caroline Krüger

Regular Lectures:

• Clinical Vaccine Development & Biomanufacturing (Yearly, University of Oxford)

• Human and Veterinary Vaccinology (Yearly, University of Oxford) • MIPS Modul 12 (Vaccinology course at ETH) • Journal Club for students on Immunology (ETH, yearly) • Immuno III lecture (ETH, yearly) • Bio 430 (Parktikum, Univerity of Zürich, yearly).

Research Methodology:

• Extensive Experience with mouse in vivo work • Extensive Experience with assessing B and T cell responses in vivo and in vitro • Extensive Experience in handling viruses • Extensive Experience in generation of virus-like particle- based vaccines

5

• Extensive Experience in performing phase I/II clinical studies • Extensive experience in starting spin-off companies and generating intellectual

property

Focus of Research My research has been dominated by the question how immune responses are regulated and how innate immune responses influence adaptive immunity. Viruses, virus-like particles and bacteria have been used to probe the protective capacity of the induced immune responses. Key problems that have been addressed are how optimal T and B cell responses are induced and maintained and how they are influenced by toll-like receptor stimulation. Understanding the cellular networks of the immune system is of significant medical interest since i) prophylactic vaccines, which are the most effective medical intervention known to date, are based on the induction of long-lived immune responses and ii) a deregulated immune system is the underlying cause of many chronic diseases and autoimmunity. In the last 10 years, I have taken the basic research performed in mice one step further and several clinical trials have been performed or are now ongoing. Clinical proof of concept has been obtained in 4 different indications (Smoking cessation, allergy, asthma and hypertension). Collaborative studies in Alzheimer`s disease are ongoing and a testing of a novel vaccine against influenza virus is expected to commence in Singapore during in the next 9 months. Some of the key findings and achievements are summarized below:

• A large number of studies have been performed in mice analyzing how stimulation of the innate immune system influences the induction of specific T and B cell responses (137-139, 141, 144, 146, 157, 158, 159, 165, 166, 175, 177). Virus-like particles and viruses were used for all studies.

• Another large number of studies in mice has been performed design vaccines by giving them a viral fingerprint (134, 135, 147, 151, 153, 160, 163, 164, 168, 178).

• Epitope repetitiveness has been established as a geometric pathogen-associated molecular pattern (PAMP) (review 39, 183). This offers an explanation for the high immunogenicity of viruses.

• The role of IL-1a, IL-1b, and membrane bound versus soluble TNF has been tested in murine models of tuberculosis and listeria (142, 174).

• A novel vaccine platform has been developed with proof-of-concept in humans in 5 indications (Smoking cessation, allergy, asthma, and hypertension). Smoking cessation has been partnered with Novartis after phase II (136, 148, 150, 161, 167, 169, 188).

• Partnership with Pfizer Animal Health on two vaccines developed by Cytos. • Partnership with Pfizer on 2 human vaccines. • Partnership with Lonza on expression system • Preclinical proof-of-concept has been obtained for vaccines against flu, pandemic

flu, West-Nile Virus and Dengue Virus. Development of the flu vaccine is

6

currently performed with A*Star in Singapore and clinical studies should be initiated Q2 2012 (170, 171, 184).

• Partnerships with the NIH as well as the US army for the development of a vaccine against malaria are ongoing.

• A virus-based functional genomics technology has been established allowing to perform global screens for proteins with pre-determined biological activity. This allowed the cloning of several important molecules (93, 109, 115, 127, 133).

• The functional genomics technology has been modified to allow cloning of fully human mAbs (149, 156, 176, 181). The latter technology has been sold to Intercell (CHF 22 Mio).

• Development of a novel cancer vaccine platform (169 and 182).

7

List of Publications: h-index: 82, Google Scholar Total Number of Citations: ca. 19`000 Research Articles 1. Bachmann, M.F., U.H. Rohrer, T.M. Kundig, K. Burki, H. Hengartner, and R.M. Zinkernagel. 1993. The influence of antigen organization on B cell responsiveness. Science 262:1448-1451. Impact: 31 2. Bachmann, M.F., T.M. Kundig, C.P. Kalberer, H. Hengartner, and R.M. Zinkernagel. 1993. Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses. J Virol 67:3917-3922. Impact: 4.9 3. Kundig, T.M., M.F. Bachmann, L. Lefrancois, L. Puddington, H. Hengartner, and R.M. Zinkernagel. 1993. Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. J Immunol 150:4450-4456. Impact: 5.5 4. Molina, T.J., M.F. Bachmann, T.M. Kundig, R.M. Zinkernagel, and T.W. Mak. 1993. Peripheral T cells in mice lacking p56lck do not express significant antiviral effector functions. J Immunol 151:699-706. Impact: 5.5 5. Kopf, M., G. Le Gros, M.Bachmann, M.C. Lamers, H. Bluethmann, and G. Kohler. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362:245-248. Impact: 38.8 6. Kundig, T.M., H. Schorle, M.F. Bachmann, H. Hengartner, R.M. Zinkernagel, and I. Horak. 1993. Immune responses in interleukin-2-deficient mice. Science 262:1059-1061. Impact: 31 7. Castelmur, I., C. DiPaolo, M.F. Bachmann, H. Hengartner, R.M. Zinkernagel, and T.M. Kundig. 1993. Comparison of the sensitivity of in vivo and in vitro assays for detection of antiviral cytotoxic T cell activity. Cell Immunol 151:460-466. Impact: 2.1

8

8. Kundig, T.M., I. Castelmur, M.F. Bachmann, D. Abraham, D. Binder, H. Hengartner, and R.M. Zinkernagel. 1993. Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus. J Virol 67:3680-3683. Impact: 4.9 9. Bachmann, M.F., T.M. Kundig, C.P. Kalberer, H. Hengartner, and R.M. Zinkernagel. 1994. How many specific B cells are needed to protect against a virus? J Immunol 152:4235-4241. Impact: 5.5 10. Bachmann, M.F., C. Bast, H. Hengartner, and R.M. Zinkernagel. 1994. Immunogenicity of a viral model vaccine after different inactivation procedures. Med Microbiol Immunol (Berl) 183:95-104. Impact: 3.5 11. Bachmann, M.F., T.M. Kundig, G. Freer, Y. Li, C.Y. Kang, D.H. Bishop, H. Hengartner, and R.M. Zinkernagel. 1994. Induction of protective cytotoxic T cells with viral proteins. Eur J Immunol 24:2228-2236. Impact: 5 12. Bachmann, M.F., T.M. Kundig, B. Odermatt, H. Hengartner, and R.M. Zinkernagel. 1994. Free recirculation of memory B cells versus antigen-dependent differentiation to antibody-forming cells. J Immunol 153:3386-3397. Impact: 5.5 13. Bachmann, M.F., T.M. Kundig, H. Hengartner, and R.M. Zinkernagel. 1994. Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen. Eur J Immunol 24:2567-2570. Impact: 5 14. Bachmann, M.F., U.H. Rohrer, U. Steinhoff, K. Burki, S. Skuntz, H. Arnheiter, H. Hengartner, and R.M. Zinkernagel. 1994. T helper cell unresponsiveness: rapid induction in antigen-transgenic and reversion in non-transgenic mice. Eur J Immunol 24:2966-2973. Impact: 5 15. Bachmann, M.F., H. Hengartner, and R.M. Zinkernagel. 1994. Immunization with recombinant protein: conditions for cytotoxic T cell and/or antibody induction. Med Microbiol Immunol (Berl) 183:315-324. Impact: 3.5 16. Rahemtulla, A., T.M. Kundig, A. Narendran, M.F.Bachmann, M. Julius, C.J. Paige, P.S. Ohashi, R.M. Zinkernagel, and T.W. Mak. 1994. Class II major histocompatibility complex-restricted T cell function in CD4-deficient mice. Eur J Immunol 24:2213-2218.

9

Impact: 5.5 17. Freer, G., C. Burkhart, I. Ciernik, M.F. Bachmann, H. Hengartner, and R.M. Zinkernagel. 1994. Vesicular stomatitis virus Indiana glycoprotein as a T-cell-dependent and -independent antigen. J Virol 68:3650-3655. Impact: 4.9 18. M.F. Bachmann* , Roost, H.P.*, A. Haag, U. Kalinke, V. Pliska, H. Hengartner, and R.M. Zinkernagel. 1995. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc Natl Acad Sci U S A 92:1257-1261.* Equal Contribution Impact: 9.7 19. Bachmann, M.F. , J.F. Conscience, R. Probstmeier, S. Carbonetto, and M. Schachner. 1995. Recognition molecules myelin-associated glycoprotein and tenascin-C inhibit integrin-mediated adhesion of neural cells to collagen. J Neurosci Res 40:458-470. Impact: 3 20. Bachmann, M.F., A. Oxenius, H. Pircher, H. Hengartner, P.A. Ashton-Richardt, S. Tonegawa, and R.M. Zinkernagel. 1995. TAP1-independent loading of class I molecules by exogenous viral proteins. Eur J Immunol 25:1739-1743. Impact: 5 21. Bachmann, M.F., H. Schorle, R. Kuhn, W. Muller, H. Hengartner, R.M. Zinkernagel, and I. Horak. 1995. Antiviral immune responses in mice deficient for both interleukin-2 and interleukin-4. J Virol 69:4842-4846. Impact: 4.9 22. Bachmann, M.F., A. Oxenius, T.W. Mak, and R.M. Zinkernagel. 1995. T cell development in CD8-/- mice. Thymic positive selection is biased toward the helper phenotype. J Immunol 155:3727-3733. Impact: 5.5 23. Bachmann, M.F., H. Hengartner, and R.M. Zinkernagel. 1995. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur J Immunol 25:3445-3451. Impact: 4.9 24. Kundig, T.M., M.F. Bachmann, C. DiPaolo, J.J. Simard, M. Battegay, H. Lother, A. Gessner, K. Kuhlcke, P.S. Ohashi, H. Hengartner, and et al. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268:1343-1347. Impact: 31 25. Oxenius, A., M.F. Bachmann, P.G. Ashton-Rickardt, S. Tonegawa, R.M. Zinkernagel, and H. Hengartner. 1995. Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular

10

compartmentalization, invariant chain and the TAP transporter system. Eur J Immunol 25:3402-3411. Impact: 4.9 26. Gilfillan, S., M. Bachmann, S. Trembleau, L. Adorini, U. Kalinke, R. Zinkernagel, C. Benoist, and D. Mathis. 1995. Efficient immune responses in mice lacking N-region diversity. Eur J Immunol 25:3115-3122. Impact: 4.9 27. Battegay, M., M.F. Bachmann, C. Burhkart, S. Viville, C. Benoist, D. Mathis, H. Hengartner, and R.M. Zinkernagel. 1996. Antiviral immune responses of mice lacking MHC class II or its associated invariant chain. Cell Immunol 167:115-121. Impact: 2.2 28. Fehr, T., M.F. Bachmann, H. Bluethmann, H. Kikutani, H. Hengartner, and R.M. Zinkernagel. 1996. T-independent activation of B cells by vesicular stomatitis virus: no evidence for the need of a second signal. Cell Immunol 168:184-192. Impact: 2.2 29. Kundig, T.M., A. Shahinian, K. Kawai, H.W. Mittrucker, E. Sebzda, M.F. Bachmann, T.W. Mak, and P.S. Ohashi. 1996. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 5:41-52. Impact: 19.8 30. Bachmann, M.F., B. Odermatt, H. Hengartner, and R.M. Zinkernagel. 1996. Induction of long-lived germinal centers associated with persisting antigen after viral infection. J Exp Med 183:2259-2269. Impact: 13.2 31. Oxenius, A., K.A. Campbell, C.R. Maliszewski, T. Kishimoto, H. Kikutani, H. Hengartner, R.M. Zinkernagel, and M.F. Bachmann. 1996. CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med 183:2209-2218. Impact: 13.2 32. Schmits, R., T.M. Kundig, D.M. Baker, G. Shumaker, J.J. Simard, G. Duncan, A. Wakeham, A. Shahinian, A. van der Heiden, M.F. Bachmann, P.S. Ohashi, T.W. Mak, and D.D. Hickstein. 1996. LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J Exp Med 183:1415-1426. Impact: 13.2 33. Speiser, D.E., E. Sebzda, T. Ohteki, M.F. Bachmann, K. Pfeffer, T.W. Mak, and P.S. Ohashi. 1996. Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol 26:3055-3060.

11

Impact: 5 34. Bachmann, M.F., M.B. Lutz, G.T. Layton, S.J. Harris, T. Fehr, M. Rescigno, and P. Ricciardi-Castagnoli. 1996. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 26:2595-2600. Impact: 5 35. Bachmann, M.F., E. Sebzda, T.M. Kundig, A. Shahinian, D.E. Speiser, T.W. Mak, and P.S. Ohashi. 1996. T cell responses are governed by avidity and co-stimulatory thresholds. Eur J Immunol 26:2017-2022. Impact: 5 36. Brundler, M.A., P. Aichele, M. Bachmann, D. Kitamura, K. Rajewsky, and R.M. Zinkernagel. 1996. Immunity to viruses in B cell-deficient mice: influence of antibodies on virus persistence and on T cell memory. Eur J Immunol 26:2257-2262. Impact: 5 37. Kundig, T.M., M.F. Bachmann, S. Oehen, U.W. Hoffmann, J.J. Simard, C.P. Kalberer, H. Pircher, P.S. Ohashi, H. Hengartner, and R.M. Zinkernagel. 1996. On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci U S A 93:9716-9723. Impact: 9.5 38. Holtschke, T., J. Lohler, Y. Kanno, T. Fehr, N. Giese, F. Rosenbauer, J. Lou, K.P. Knobeloch, L. Gabriele, J.F. Waring, M.F. Bachmann, R.M. Zinkernagel, H.C. Morse, 3rd, K. Ozato, and I. Horak. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87:307-317. Impact: 32 39. Fehr, T., G. Schoedon, B. Odermatt, T. Holtschke, M. Schneemann, M.F. Bachmann, T.W. Mak, I. Horak, and R.M. Zinkernagel. 1997. Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis. J Exp Med 185:921-931. Impact: 13.2 40. Bachmann, M.F., T.M. Kundig, H. Hengartner, and R.M. Zinkernagel. 1997. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without "memory T cells"? Proc Natl Acad Sci U S A 94:640-645. Impact: 9.7 41. Speiser, D.E., M.F. Bachmann, T.W. Frick, K. McKall-Faienza, E. Griffiths, K. Pfeffer, T.W. Mak, and P.S. Ohashi. 1997. TNF receptor p55 controls early acute graft-versus-host disease. J Immunol 158:5185-5190.

12

Impact: 5.5 42. Speiser, D.E., M.F. Bachmann, A. Shahinian, T.W. Mak, and P.S. Ohashi. 1997. Acute graft-versus-host disease without costimulation via CD28. Transplantation 63:1042-1044. Impact: 3.8 43. Fehr, T., M.F. Bachmann, E. Bucher, U. Kalinke, F.E. Di Padova, A.B. Lang, H. Hengartner, and R.M. Zinkernagel. 1997. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 185:1785-1792. Impact: 13.2 44. Oxenius, A., and M.F. Bachmann. 1997. Similar ligand densities required for restimulation and effector function of cytotoxic T cells. Cell Immunol 179:16-21. Impact: 2.1 45. Oxenius, A., M.F. Bachmann, D. Mathis, C. Benoist, R.M. Zinkernagel, and H. Hengartner. 1997. Functional in vivo MHC class II loading by endogenously synthesized glycoprotein during viral infection. J Immunol 158:5717-5726. Impact: 5.5 46. Bachmann, M.F., U. Kalinke, A. Althage, G. Freer, C. Burkhart, H. Roost, M. Aguet, H. Hengartner, and R.M. Zinkernagel. 1997. The role of antibody concentration and avidity in antiviral protection. Science 276:2024-2027. Impact: 31 47. Bachmann, M.F., D.E. Speiser, and P.S. Ohashi. 1997. Functional maturation of an antiviral cytotoxic T-cell response. J Virol 71:5764-5768. Impact: 4.9 48. Bachmann, M.F., T. Fehr, G. Freer, H. Hengartner, and R.M. Zinkernagel. 1997. Correlation of tolerogenicity of a viral antigen with its immunogenicity. J Immunol 158:5106-5111. Impact: 5.5 49. Bachmann, M.F., T.M. Kundig, D.E. Speiser, K. McKall-Faienza, K. Kishara, T.W. Mak, and P.S. Ohashi. 1997. T-cell-independent antiviral B cell responses in CD45-deficient mice. Cell Immunol 175:12-15. Impact: 2.2 50. Bachmann, M.F., S. Mariathasan, D. Bouchard, D.E. Speiser, and P.S. Ohashi. 1997. Four types of Ca2+ signals in naive CD8+ cytotoxic T cells after stimulation with T cell agonists, partial agonists and antagonists. Eur J Immunol 27:3414-3419. Impact: 5

13

51. Bachmann, M.F., A. Oxenius, D.E. Speiser, S. Mariathasan, H. Hengartner, R.M. Zinkernagel, and P.S. Ohashi. 1997. Peptide-induced T cell receptor down-regulation on naive T cells predicts agonist/partial agonist properties and strictly correlates with T cell activation. Eur J Immunol 27:2195-2203. Impact: 5 52. Waterhouse, P., M.F. Bachmann, J.M. Penninger, P.S. Ohashi, and T.W. Mak. 1997. Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor-transgenic CTLA-4-deficient mice. Eur J Immunol 27:1887-1892. Impact: 5 53. Bachmann, M.F., D.R. Littman, and X.C. Liao. 1997. Antiviral immune responses in Itk-deficient mice. J Virol 71:7253-7257. Impact: 4.9 54. Bachmann, M.F.*, Nishina, H.*, , A.J. Oliveira-dos-Santos, I. Kozieradzki, K.D. Fischer, B. Odermatt, A. Wakeham, A. Shahinian, H. Takimoto, A. Bernstein, T.W. Mak, J.R. Woodgett, P.S. Ohashi, and J.M. Penninger. 1997. Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes. J Exp Med 186:941-953. * Equal Contribution Impact: 13.2 55. Speiser, D.E., R. Miranda, A. Zakarian, M.F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R.M. Zinkernagel, and P.S. Ohashi. 1997. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186:645-653. Impact: 13.2 56. Bachmann, M.F., K. McKall-Faienza, R. Schmits, D. Bouchard, J. Beach, D.E. Speiser, T.W. Mak, and P.S. Ohashi. 1997. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 7:549-557. Impact: 19.8 57. Bachmann, M.F., T. Ohteki, K.M. Faienza, A. Zakarian, D. Kagi, D.E. Speiser, and P.S. Ohashi. 1997. Altered peptide ligands trigger perforin- rather than Fas-dependent cell lysis. J Immunol 159:4165-4170. Impact: 5 58. Bachmann, M.F., P. Waterhouse, D.E. Speiser, K. McKall-Faienza, T.W. Mak, and P.S. Ohashi. 1998. Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells. J Immunol 160:95-100. Impact: 5.5

14

59. Oxenius, A., M.F. Bachmann, R.M. Zinkernagel, and H. Hengartner. 1998. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur J Immunol 28:390-400. Impact: 5 60. McKall-Faienza, K.J., K. Kawai, T.M. Kundig, B. Odermatt, M.F. Bachmann, A. Zakarian, T.W. Mak, and P.S. Ohashi. 1998. Absence of TNFRp55 influences virus-induced autoimmunity despite efficient lymphocytic infiltration. Int Immunol 10:405-412. Impact: 3.4 61. Yoshida, H., H. Nishina, H. Takimoto, L.E. Marengere, A.C. Wakeham, D. Bouchard, Y.Y. Kong, T. Ohteki, A. Shahinian, M. Bachmann, P.S. Ohashi, J.M. Penninger, G.R. Crabtree, and T.W. Mak. 1998. The transcription factor NF-ATc1 regulates lymphocyte proliferation and Th2 cytokine production. Immunity 8:115-124. Impact: 19.8 62. Salzmann, M., and M.F. Bachmann. 1998. The role of T cell receptor dimerization for T cell antagonism and T cell specificity. Mol Immunol 35:271-277. Impact: 2.9 63. Salzmann, M., and M.F. Bachmann. 1998. Estimation of maximal affinities between T-cell receptors and MHC/peptide complexes. Mol Immunol 35:65-71. Impact: 2.9 64. Bachmann, M.F., M. Salzmann, A. Oxenius, and P.S. Ohashi. 1998. Formation of TCR dimers/trimers as a crucial step for T cell activation. Eur J Immunol 28:2571-2579. Impact: 5 65. Bachmann, M.F., D.E. Speiser, A. Zakarian, and P.S. Ohashi. 1998. Inhibition of TCR triggering by a spectrum of altered peptide ligands suggests the mechanism for TCR antagonism. Eur J Immunol 28:3110-3119. Impact: 5 66. Speiser, D.E., M.F.Bachmann, M.J. Soloski, J. Forman, and P.S. Ohashi. 1998. Alloreactive cytotoxic T cells recognize minor transplantation antigens presented by major histocompatibility complex class Ib molecules. Transplantation 66:646-650. Impact: 3.8 67. Griffiths, E., H. Ong, M.J. Soloski, M.F. Bachmann, P.S. Ohashi, and D.E. Speiser. 1998. Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I. Cancer Res 58:4682-4687. Impact: 7.8

15

68. Fehr, T., H.Y. Naim, M.F. Bachmann, A.F. Ochsenbein, P. Spielhofer, E. Bucher, H. Hengartner, M.A. Billeter, and R.M. Zinkernagel. 1998. T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. Nat Med 4:945-948. Impact: 22.8 69. Kong, Y.Y., K.D. Fischer, M.F. Bachmann, S. Mariathasan, I. Kozieradzki, M.P. Nghiem, D. Bouchard, A. Bernstein, P.S. Ohashi, and J.M. Penninger. 1998. Vav regulates peptide-specific apoptosis in thymocytes. J Exp Med 188:2099-2111. Impact: 13.2 70. Mariathasan, S., M.F. Bachmann, D. Bouchard, T. Ohteki, and P.S. Ohashi. 1998. Degree of TCR internalization and Ca2+ flux correlates with thymocyte selection. J Immunol 161:6030-6037. Impact: 5.5 71. Bachmann, M.F., M. Barner, A. Viola, and M. Kopf. 1999. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur J Immunol 29:291-299. Impact: 5 72. Bachmann, M.F., B. Ecabert, and M. Kopf. 1999. Influenza virus: a novel method to assess viral and neutralizing antibody titers in vitro. J Immunol Methods 225:105-111. Impact: 2.2 73. Bachmann, M.F., B.R. Wong, R. Josien, R.M. Steinman, A. Oxenius, and Y. Choi. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 189:1025-1031. Impact: 13.2 74. Penninger, J.M., K.D. Fischer, T. Sasaki, I. Kozieradzki, J. Le, K. Tedford, K. Bachmaier, P.S. Ohashi, and M.F. Bachmann. 1999. The oncogene product Vav is a crucial regulator of primary cytotoxic T cell responses but has no apparent role in CD28-mediated co-stimulation. Eur J Immunol 29:1709-1718. Impact: 5 75. Ruedl, C., M. Kopf, and M.F. Bachmann. 1999. CD8(+) T cells mediate CD40-independent maturation of dendritic cells in vivo. J Exp Med 189:1875-1884. Impact: 13.2 76. Bachmann, M.F., A. Gallimore, S. Linkert, V. Cerundolo, A. Lanzavecchia, M. Kopf, and A. Viola. 1999. Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. J Exp Med 189:1521-1530. Impact: 13.2

16

77. Bachmann, M.F., D.E. Speiser, T.W. Mak, and P.S. Ohashi. 1999. Absence of co-stimulation and not the intensity of TCR signaling is critical for the induction of T cell unresponsiveness in vivo. Eur J Immunol 29:2156-2166. Impact: 5 78. Bachmann, M.F., L. Nitschke, C. Krawczyk, K. Tedford, P.S. Ohashi, K.D. Fischer, and J.M. Penninger. 1999. The guanine-nucleotide exchange factor Vav is a crucial regulator of B cell receptor activation and B cell responses to nonrepetitive antigens. J Immunol 163:137-142. Impact: 5.5 79. Marmor, M.D., M.F. Bachmann, P.S. Ohashi, T.R. Malek, and M. Julius. 1999. Immobilization of glycosylphosphatidylinositol-anchored proteins inhibits T cell growth but not function. Int Immunol 11:1381-1393. Impact: 3.4 80. Bachmann, M.F., G. Kohler, B. Ecabert, T.W. Mak, and M. Kopf. 1999. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol 163:1128-1131. Impact: 5.5 81. DeBenedette, M.A., T. Wen, M.F. Bachmann, P.S. Ohashi, B.H. Barber, K.L. Stocking, J.J. Peschon, and T.H. Watts. 1999. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol 163:4833-4841. Impact: 5.5 82. Ruedl, C., and M.F. Bachmann. 1999. CTL priming by CD8(+) and CD8(-) dendritic cells in vivo. Eur J Immunol 29:3762-3767. Impact: 5 83. Bachmann, M.F., M. Barner, and M. Kopf. 1999. CD2 sets quantitative thresholds in T cell activation. J Exp Med 190:1383-1392. Impact: 13.2 84. Ohteki, T., A. Hessel, M.F. Bachmann, A. Zakarian, E. Sebzda, M.S. Tsao, K. McKall-Faienza, B. Odermatt, and P.S. Ohashi. 1999. Identification of a cross-reactive self ligand in virus-mediated autoimmunity. Eur J Immunol 29:2886-2896. Impact: 5 85. Kopf, M., C. Ruedl, N. Schmitz, A. Gallimore, K. Lefrang, B. Ecabert, B. Odermatt, and M.F. Bachmann. 1999. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity 11:699-708.

17

Impact: 19.8 86. Cenci, E., A. Mencacci, G. Del Sero, A. Bacci, C. Montagnoli, C.F. d'Ostiani, P. Mosci, M. Bachmann, F. Bistoni, M. Kopf, and L. Romani. 1999. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 180:1957-1968. Impact: 5.8 87. van Den Broek, M., M.F. Bachmann, G. Kohler, M. Barner, R. Escher, R. Zinkernagel, and M. Kopf. 2000. IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2. J Immunol 164:371-378. Impact: 5.5 88. Karrer, U., C. Lopez-Macias, A. Oxenius, B. Odermatt, M.F. Bachmann, U. Kalinke, H. Bluethmann, H. Hengartner, and R.M. Zinkernagel. 2000. Antiviral B cell memory in the absence of mature follicular dendritic cell networks and classical germinal centers in TNFR1-/- mice. J Immunol 164:768-778. Impact: 5.5 89. Kopf, M., A.J. Coyle, N. Schmitz, M. Barner, A. Oxenius, A. Gallimore, J.C. Gutierrez-Ramos, and M.F. Bachmann. 2000. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection. J Exp Med 192:53-61. Impact: 13.2 90. Boorsma, M., L. Nieba, D. Koller, M.F. Bachmann, J.E. Bailey, and W.A. Renner. 2000. A temperature-regulated replicon-based DNA expression system. Nat Biotechnol 18:429-432. Impact: 32.4 91. Ruedl, C., P. Koebel, M.Bachmann, M. Hess, and K. Karjalainen. 2000. Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes. J Immunol 165:4910-4916. Impact: 5.5 92. Ruedl, C., M.F. Bachmann and M. Kopf. 2000. The antigen dose determines T helper subset development by regulation of CD40 ligand. Eur J Immunol 30:2056-2064 Impact: 5 93. Bachmann, M.F., A. Gallimore, E. Jones, B. Ecabert, H. Acha-Orbea, and M. Kopf. 2001. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur J Immunol 31:450-458. Impact: 5

18

94. Koller, D., C. Ruedl, M. Loetscher, J. Vlach, S. Oehen, K. Oertle, M. Schirinzi, E. Deneuve, R. Moser, M. Kopf, J.E. Bailey, W. Renner, and M.F. Bachmann. 2001. A high-throughput alphavirus-based expression cloning system for mammalian cells. Nat Biotechnol 19:851-855. Impact: 32.4 95. Storni, T., F. Lechner, I. Erdmann, T. Bachi, A. Jegerlehner, T. Dumrese, T.M. Kundig, C. Ruedl, and M.F. Bachmann. 2002. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 168:2880-2886. Impact: 5 96. Kopf, M., B. Abel, A. Gallimore, M. Carroll, and M.F. Bachmann. 2002. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 8:373-378. Impact: 22.8 97. Kopf, M., F. Brombacher, and M.F. Bachmann. 2002. Role of IgM antibodies versus B cells in influenza virus-specific immunity. Eur J Immunol 32:2229-2236. Impact: 5 98. Ruedl, C., T. Storni, F. Lechner, T. Bachi, and M.F. Bachmann. 2002. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 32:818-825. Impact: 5 99. Jegerlehner, A., A. Tissot, F. Lechner, P. Sebbel, I. Erdmann, T. Kundig, T. Bachi, T. Storni, G. Jennings, P. Pumpens, W. Renner, and M.F. Bachmann. 2002. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20:3104. Impact: 3.5 100. Boorsma, M., S. Hoenke, A. Marrero, R. Fischer, J.E. Bailey, W.A. Renner, and M.F. Bachmann. 2002. Bioprocess applications of a Sindbis virus-based temperature-inducible expression system. Biotechnol Bioeng 79:602-609. Impact: 3.6 101. Jegerlehner, A., T. Storni, G. Lipowsky, M. Schmid, P. Pumpens, and M.F. Bachmann. 2002. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol 32:3305-3314. Impact: 3.5

19

102. Boorsma, M., P. Saudan, H. Pfruender, J.E. Bailey, S. Schlesinger, W.A. Renner, and M.F. Bachmann. 2003. Alphavirus cDNA-based expression vectors: Effects of RNA transcription and nuclear export. Biotechnol Bioeng 81:553-562. Impact: 3.6 103. Schwarz, K., T. Storni, V. Manolova, A. Didierlaurent, J.C. Sirard, P. Rothlisberger, and M.F. Bachmann. 2003. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol 33:1465-1470. Impact: 5 104. Storni, T., and M.F. Bachmann. 2003. On the role of APC-activation for in vitro versus in vivo T cell priming. Cell Immunol 225:1-11. Impact: 2.1 105. Storni, T., C. Ruedl, W.A. Renner, and M.F. Bachmann. 2003. Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol 171:795-801. Impact: 5.5 106. Piossek, C., K.H. Thierauch, J. Schneider-Mergener, R. Volkmer-Engert, M.F. Bachmann, T. Korff, H.G. Augustin, and L. Germeroth. 2003. Potent inhibition of angiogenesis by D,L-peptides derived from vascular endothelial growth factor receptor 2. Thromb Haemost 90:501-510. Impact: 6.1 107. Bachmann, M.F., L. Hunziker, R.M. Zinkernagel, T. Storni, and M. Kopf. 2004. Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key. Eur J Immunol 34:317-326. Impact: 5 108. Storni, T., C. Ruedl, K. Schwarz, R.A. Schwendener, W.A. Renner, and M.F. Bachmann. 2004. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 172:1777-1785. Impact: 5 109. Storni, T., and M.F. Bachmann. 2004. Loading of the MHC class I and MHC class II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J Immunol 172:6129-6135 Impact: 5 110. Sirena, D., B. Lilienfeld, M. Eisenhut, S. Kalin, K. Boucke, R.R. Beerli, L. Vogt, C. Ruedl, M.F. Bachmann, U.F. Greber, and S. Hemmi. 2004. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 78:4454-4462.

20

Impact: 4.9 111. Battig, P., P. Saudan, T. Gunde, and M.F. Bachmann. 2004. Enhanced apoptotic activity of a structurally optimized form of galectin-1. Mol Immunol 41:9-18. Impact: 2.9 112. Jegerlehner, A., N. Schmitz, T. Storni, and M.F. Bachmann. 2004. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172:5598-5605. Impact: 5.5 113. Freer, G., S. Giannecchini, A. Tissot, M.F. Bachmann, P. Rovero, P.F. Serres, and M. Bendinelli. 2004. Dissection of seroreactivity against the tryptophan-rich motif of the feline immunodeficiency virus transmembrane glycoprotein. Virology 322:360-369. Impact: 4.9 114. Schlaepfer, E., A. Audige, B. von Beust, V. Manolova, M. Weber, H. Joller, M.F. Bachmann, T.M. Kundig, and R.F. Speck. 2004. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J Virol 78:12344-12354. Impact: 4.9 115 Gatto, D., C. Ruedl, B. Odermatt, and M.F. Bachmann. 2004. Rapid response of marginal zone B cells to viral particles. J Immunol 173:4308-4316. Impact: 5.5 116. Bachmann, M., K. Schwarz, P. Wolint, E. Meijerink, S. Martin, V. Manolova, and A. Oxenius. 2004. Cutting edge: distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8+ T cells. J Immunol 173:2217-2221. Impact: 5.5 117. Ruedl, C., K. Schwarz, A. Jegerlehner, T. Storni, V. Manolova, and M.F. Bachmann. 2005. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 79:717-724. Impact: 4.9 118. Spohn, G., K. Schwarz, P. Maurer, H. Illges, N. Rajasekaran, Y. Choi, G.T. Jennings, and M.F. Bachmann. 2005. Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol 175:6211-6218. Impact: 5.5 119. Abel, B., S. Freigang, M.F. Bachmann, U. Boschert, and M. Kopf. 2005. Osteopontin is not required for the development of Th1 responses and viral immunity. J

21

Immunol 175:6006-6013. Impact: 5.5 120. Marsland, B.J., C. Nembrini, N. Schmitz, B. Abel, S. Krautwald, M.F. Bachmann, and M. Kopf. 2005. Innate signals compensate for the absence of PKC {theta} during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci U S A 102:14374-14379. Impact: 9.7 121. Bachmann, M.F., P. Wolint, K. Schwarz, P. Jager, and A. Oxenius. 2005 Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol 175:4686-4696. Impact: 5.5 122. Bachmann, M.F., P. Wolint, K. Schwarz, and A. Oxenius. 2005. Recall proliferation potential of memory CD8+ T cells and antiviral protection. J Immunol 175:4677-4685. Impact: 5.5 123. Ivanova, L., J. Brandli, P. Saudan, and M.F. Bachmann. 2005. Hybrid Sindbis/Epstein-Barr virus episomal expression vector for inducible production of proteins. Biotechniques 39:209-212. Impact: 3 124. Maurer, P., G.T. Jennings, J. Willers, F. Rohner, Y. Lindman, K. Roubicek, W.A. Renner, P. Muller, and M.F. Bachmann. 2005. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 35:2031-2040. Impact: 5 125. Schmitz, N., M. Kurrer, M.F. Bachmann, and M. Kopf. 2005. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol 79:6441-6448. Impact: 4.9 126. Battig, P., P. Saudan, T. Storni, A. Gallimore, and M.F. Bachmann. 2005. Limited in vivo reactivity of polyclonal effector cytotoxic T cells towards altered peptide ligands. Microbes Infect 7:729-737. Impact: 2.8 127. Marsland, B.J., P. Battig, M. Bauer, C. Ruedl, U. Lassing, R.R. Beerli, K. Dietmeier, L. Ivanova, T. Pfister, L. Vogt, H. Nakano, C. Nembrini, P. Saudan, M. Kopf, and M.F. Bachmann. 2005. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 22:493-505. Impact: 19.8

22

128. Gatto, D., T. Pfister, A. Jegerlehner, S.W. Martin, M. Kopf, and M.F. Bachmann. 2005. Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med 201:993 1005. Impact: 13.2 129. Schwarz, K., E. Meijerink, D.E. Speiser, A.C. Tissot, I. Cielens, R. Renhof, A. Dishlers, P. Pumpens, and M.F. Bachmann. 2005. Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur J Immunol 35:816-821. Impact: 5 130. Grundemann, C., M. Bauer, O. Schweier, N. von Oppen, U. Lassing, P. Saudan, K.F. Becker, K. Karp, T. Hanke, M.F. Bachmann, and H. Pircher. 2006. Cutting edge: identification of e-cadherin as a ligand for the murine killer cell lectin-like receptor g1. J Immunol 176:1311-1315. Impact: 5.5 131 Bachmann, M.F., R.R. Beerli, P. Agnellini, P. Wolint, K. Schwarz, and A. Oxenius. 2006. Long-lived memory CD8(+) T cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur J Immunol.36:842-854 Impact: 5 132 Kundig, T.M., G. Senti, G. Schnetzler, C. Wolf, B.M. Prinz Vavricka, A. Fulurija, A F. Hennecke, K. Sladko, G.T. Jennings, and M.F. Bachmann. 2006. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 117:1470-1476. Impact: 12 133 Vogt, L., N. Schmitz, M.O. Kurrer, M. Bauer, H. Hinton, S. Behnke, D. Gatto, P. Sebbel, R.R. Beerli, I. Sonderegger, M. Kopf, P. Saudan, and M.F. Bachmann. 2006. VSIG4, a B7-family related protein, is a negative regulator of T cell activation. J Clin Invest 116:2817-2826. Impact: 13 134 Rohn TA, G.T. Jennings, M. Hernandez, P. Grest, M. Beck, Y. Zou, M. Kopf, M.F. Bachmann. 2006. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol. 36:2857-2867. Impact: 5 135 Sonderegger I, T.A. Rohn, M.O. Kurrer, G. Iezzi, Y. Zou, R.A. Kastelein, M.F. Bachmann and M. Kopf .2006. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol. 36:2849-2856. Impact: 5 136 Ambühl, P., A. Tissot, A. Fulurija, P. Maurer, J. Nussberger, R. Sabat, V. Nief, C. Schellekens, K. Sladko, K. Roubicek, T. Pfister, M. Rettenbacher, H.-D. Volk, F.

23

Wagner, P. Müller, G. Jennings, and M. F. Bachmann. 2006. A Therapeutic Vaccine for Hypertension Based on Virus-like Particles: Preclinical Efficacy and Phase I Safety and Immunogenicity. J Hypertens 25:63-72. Impact: 3.8 137 Gatto, D., S.W. Martin, J. Bessa, E. Pellicioli, P. Saudan, H. J. Hinton and M. F. Bachmann. 2007. Regulation of memory antibody levels: the role of persisting antigen versus plasma cell lifespan. J Immunol, 178:67-76 Impact: 5.5 138 Gatto, D., M. Bauer, S. W. Martin, and M. F. Bachmann. Heterogeneous antibody repertoire of marginal zone B cells specific for viral particles. Microbes and Infection, 9: 391-399 Impact: 2.8 139 Jegerlehner, A., P. Maurer, J. Bessa, H. J. Hinton, M. Kopf and M. F. Bachmann. 2007. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol, 178:2415-2420 Impact: 5.5 140 Boulter , J.M., N. Schmitz, A.K. Sewell, A.J. Godkin, M.F. Bachmann and A.M. Gallimore. (2007). Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol., 37 :798-806 Impact: 5 141 Bachmann M.F., Wolint P., Walton S., Schwarz K., and A. Oxenius 2007. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur J Immunol. 37:1502-12. Impact: 5 142 Spohn G., R. Guler, P. Johansen, I. Keller, M. Jacobs, M. Beck, F. Rohner, M. Bauer, K. Dietmeier T.M. Kundig, G.T. Jennings, F. Brombacher, M.F. Bachmann 2007 A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol. 178:7450-7. Impact: 5 143 Mueller S.N., K.A. Hosiawa-Meagher,B.T. Konieczny, B.M. Sullivan, M.F. Bachmann, R.M. Locksley, R. Ahmed, and M. Matloubian.2007. Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science 317:670-4. Impact: 31 144 Bessa J., Schmitz N., Hinton H.J., Schwarz K., Jegerlehner A., M.F. Bachmann 2008. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.

24

Eur J Immunol. 38:114-26. Impact: 5 145 Won W.J., Bachmann M.F., J.F. Kearney. 2008 CD36 is differentially expressed on B cell subsets during development and in responses to antigen. J. Immunol. 180(1):230-7 Impact: 5.5 146 Agnellini P., Wiesel M., Schwarz K., Wolint P., Bachmann M.F., A. Oxenius 2008 Kinetic and mechanistic requirements for helping CD8 T cells. J Immunol. 180(3):1517-25. Impact: 5.5 147 Spohn G., Keller I., Beck M., Grest P., Jennings G.T. and M. F. Bachmann.2008 Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol., 38: 877-887 Impact: 5 148 Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., Ignatenko S., Volk H., Stocker H., Müller P., Jennings G.T., Wagner F. and M. F. Bachmann 2008. Vaccination against Angiotensin II reduces Day-Time and Early-Morning Ambulatory Blood Pressure: Results of a Randomized Placebo-Controlled Phase IIa Study with CYT006-AngQb. Lancet 371:821-827 Impact: 39 149 Beerli, R.R., M. Bauer, R.B. Buser, M. Gwerder, S. Muntwiler, P. Maurer, P Saudan, and M.F. Bachmann. 2008. Isolation of human monoclonal antibodies by mammalian cell display. Proceedings of the National Academy of Sciences of the United States of America 105:14336-14341. Impact: 9.7 150 Cornuz, J., S. Zwahlen, W.F. Jungi, J. Osterwalder, K. Klingler, G. van Melle, Y. Bangala, I. Guessous, P. Muller, J. Willers, P. Maurer, M.F. Bachmann, and T. Cerny. 2008. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PloS one 3:e2547. Impact: 3.7 151 Fulurija, A., T.A. Lutz, K. Sladko, M. Osto, P.Y. Wielinga, M.F. Bachmann, and P. Saudan. 2008. Vaccination against GIP for the treatment of obesity. PloS one 3:e3163. Impact: 3.7 152 Luckashenak, N., S. Schroeder, K. Endt, D. Schmidt, K. Mahnke, M.F. Bachmann, P. Marconi, C.A. Deeg, and T. Brocker. 2008. Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity 28:521-532. Impact: 19.8

25

153 Manolova, V., A. Flace, M. Bauer, K. Schwarz, P. Saudan, and M.F. Bachmann. 2008. Nanoparticles target distinct dendritic cell populations according to their size. European journal of immunology 38:1404-1413. Impact: 5 154 von Allmen, C.E., M. Bauer, K. Dietmeier, R.B. Buser, M. Gwerder, S. Muntwiler, S. Utzinger, P. Saudan, M.F. Bachmann, and R.R. Beerli. 2008. Identification of Ly-6K as a novel marker for mouse plasma cells. Molecular immunology 45:2727-2733. Impact: 2.9 155 Araki, K., A.P. Turner, V.O. Shaffer, S. Gangappa, S.A. Keller, M.F. Bachmann, C.P. Larsen, and R. Ahmed. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460:108-112. Impact: 38.6 156 Beerli, R.R., M. Bauer, N. Schmitz, R.B. Buser, M. Gwerder, S. Muntwiler, W.A. Renner, P. Saudan, and M.F. Bachmann. 2009. Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virology journal 6:224. Impact: 2.1 157 Bessa, J., A. Jegerlehner, H.J. Hinton, P. Pumpens, P. Saudan, P. Schneider, and M.F. Bachmann. 2009. Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol 183:3788-3799. Impact: 5.5 158 Keller, S.A., M. Bauer, V. Manolova, S. Muntwiler, P. Saudan, and M.F. Bachmann. 2010. Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles. J Immunol 184:26-29. Impact: 5.5 159 Keller, S.A., C.E. von Allmen, H.J. Hinton, M. Bauer, S. Muntwiler, K. Dietmeier, P. Saudan, and M.F. Bachmann. 2009. Follicular and marginal zone B cells fail to cross-present MHC class I-restricted epitopes derived from viral particles. J Immunol 182:6261-6266. Impact: 5.5 160 Schmitz, N., K. Dietmeier, M. Bauer, M. Maudrich, S. Utzinger, S. Muntwiler, P. Saudan, and M.F. Bachmann. 2009. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. The Journal of experimental medicine 206:1941-1955. Impact: 13.2

26

161 Senti, G., P. Johansen, S. Haug, C. Bull, C. Gottschaller, P. Muller, T. Pfister, P. Maurer, M.F. Bachmann, N. Graf, and T.M. Kundig. 2009. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 39:562-570. Impact: 4.8 162 von Allmen, C.E., N. Schmitz, M. Bauer, H.J. Hinton, M.O. Kurrer, R.B. Buser, M. Gwerder, S. Muntwiler, T. Sparwasser, R.R. Beerli, and M.F. Bachmann. 2009. Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America 106:11673-11678. Impact: 9.7 163 Zou, Y., I. Sonderegger, G. Lipowsky, G.T. Jennings, N. Schmitz, M. Landi, M. Kopf, and M.F. Bachmann. 2010. Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice. Vaccine 28:3192-3200. Impact: 3.5 164 Jegerlehner, A., M. Wiesel, K. Dietmeier, F. Zabel, D. Gatto, P. Saudan, and M.F. Bachmann. 2010. Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine 28:5503-5512. Impact: 3.5 165 Keller, S.A., K. Schwarz, V. Manolova, C.E. von Allmen, M.G. Kinzler, M. Bauer, S. Muntwiler, P. Saudan, and M.F. Bachmann. 2010. Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. European journal of immunology 40:103-112. Impact: 5 166 Bessa, J., M. Kopf, and M.F. Bachmann. 2010. Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol 184:4615-4619. Impact: 5 167 Klimek, L., J. Willers, A. Hammann-Haenni, O. Pfaar, H. Stocker, P. Mueller, W.A. Renner, and M.F. Bachmann. 2011. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 41:1305-1312 Impact: 4.8 168 Rohn, T.A., W.T. Ralvenius, J. Paul, P. Borter, M. Hernandez, R. Witschi, P. Grest, H.U. Zeilhofer, M.F. Bachmann, and G.T. Jennings. 2011. A virus-like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: potential long-term therapy for chronic pain. J Immunol 186:1769-1780.

27

Impact: 5.5 169 Speiser, D.E., K. Schwarz, P. Baumgaertner, V. Manolova, E. Devevre, W. Sterry, P. Walden, A. Zippelius, K.B. Conzett, G. Senti, V. Voelter, J.P. Cerottini, D. Guggisberg, J. Willers, C. Geldhof, P. Romero, T. Kundig, A. Knuth, R. Dummer, U. Trefzer, and M.F. Bachmann. 2010. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 33:848-858. Impact: 3.2 170 Spohn, G., G.T. Jennings, B.E. Martina, I. Keller, M. Beck, P. Pumpens, A.D. Osterhaus, and M.F. Bachmann. 2010. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virology journal 7:146. Impact: 2.1 171 Tissot, A.C., R. Renhofa, N. Schmitz, I. Cielens, E. Meijerink, V. Ose, G.T. Jennings, P. Saudan, P. Pumpens, and M.F. Bachmann. 2011. Versatile virus-like particle carrier for epitope based vaccines. PloS one 5:e9809. Impact: 3.7 172 Tortola, L., K. Yadava, M.F. Bachmann, C. Muller, J. Kisielow, and M. Kopf. 2011. IL-21 induces death of marginal zone B cells during chronic inflammation. Blood 116:5200-5207. Impact: 9 173 Freigang, S., F. Ampenberger, G. Spohn, S. Heer, A.T. Shamshiev, J. Kisielow, M. Hersberger, M. Yamamoto, M.F. Bachmann, and M. Kopf. 2010. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. European journal of immunology 41:2040-2051. Impact: 5 174 Songhet P, Barthel M, Röhn TA, Van Maele L, Cayet D, Sirard JC, Bachmann MF, Kopf M, Hardt WD. (2010). IL-17A/F-signaling does not contribute to the initial phase of mucosal inflammation triggered by S. Typhimurium. PLoS One.5: e13804. Impact: 3.8 175 Guler, R., S.P. Parihar, G. Spohn, P. Johansen, F. Brombacher, and M.F. Bachmann. 2011. Blocking IL-1alpha but not IL-1beta increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine 29:1339-1346. Impact: 3.5 176 Hou, B., P. Saudan, G. Ott, M.L. Wheeler, M. Ji, L. Kuzmich, L.M. Lee, R.L. Coffman, M.F. Bachmann, and A.L. DeFranco. 2011. Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 34:375-384. Impact: 19.8

28

177 Uermosi, C., R.R. Beerli, M. Bauer, V. Manolova, K. Dietmeier, R.B. Buser, T.M. Kundig, P. Saudan, and M.F. Bachmann. 2011. Mechanisms of allergen-specific desensitization. The Journal of allergy and clinical immunology 126:375-383. Impact: 12 178 Wiesel, M., N. Joller, A.K. Ehlert, J. Crouse, R. Sporri, M.F. Bachmann, and A. Oxenius. 2011. Th cells act via two synergistic pathways to promote antiviral CD8+ T cell responses. J Immunol 185:5188-5197. Impact: 5.5 179 Wiessner, C., K.H. Wiederhold, A.C. Tissot, P. Frey, S. Danner, L.H. Jacobson, G.T. Jennings, R. Luond, R. Ortmann, J. Reichwald, M. Zurini, A. Mir, M.F. Bachmann, and M. Staufenbiel. 2011. The Second-Generation Active A{beta} Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects. J Neurosci 31:9323-9331. Impact: 7.3 180 Fettelschoss A, Kistowska M, LeibundGut-Landmann S, Beer HD, Johansen P, Senti G, Contassot E, Bachmann MF, French LE, Oxenius A, Kündig TM.(2012) Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc Natl Acad Sci U S A. 2011; 108:18055-60. Impact: 9.7 181 Tars K, Kotelovica S, Lipowsky G, Bauer M, Beerli RR, Bachmann MF, Maurer P. (2012). Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody. J Mol Biol. 415:118-27. Impact: 3.9 182 Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, Speiser DE, Romero P. (2012) Virus-like particles induce robust human T-helper cell responses. Eur J Immunol. 42:330-40 Impact: 5 183 Alexander Link, Franziska Zabel, Yvonne Schnetzler, Alexander Titz, Frank, Brombacher and Martin F. Bachmann (2012). Innate Immunity Mediates Follicular Transport of Particulate but not Soluble Protein Antigen. J Immunol, 188:3724-3733 Impact: 5.5 184 Nicole Schmitz, Roger Beerli, Monika Bauer, Klaus Dietmeier, Melanie Maudrich, Philippe Saudan and Martin F. Bachmann (2012) Universal vaccine against influenza virus: linking toll-like receptor signaling to anti-viral protection. Eur J Immunol, 42:863-869 Impact: 5

29

185 Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann Haenni A, Willers J, Geldhof C, Prior JO, Kündig TM, Michielin O, Bachmann MF, Speiser DE. (2012) Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁷ T-cell responses in melanoma patients. Eur J Immunol. 42:3049-3061 Impact: 5 186 Bessa J, Zabel F, Link A, Jegerlehner A, Hinton HJ, Schmitz N, Bauer M, Kündig TM, Saudan P, Bachmann MF. (2012). Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses. Proc Natl Acad Sci U S A 109:20566-20571 Impact: 9.7 187 Tissot AC, Spohn G, Jennings GT, Shamshiev A, Kurrer MO, Windak R, Meier M, Viesti M, Hersberger M, Kündig TM, Ricci R, Bachmann MF. (2012). A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis. Eur J Immunol. 10.1002/eji.201242687. Epub, ahead of print Impact: 5 188 Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, Willers J, Stocker H, Mueller P, Bachmann MF, Renner WA. (2013) The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol. 2013 Mar;131(3):866-74. doi: Impact: 12 189 Jegerlehner A, Zabel F, Langer A, Dietmeier K, Jennings GT, Saudan P and Bachmann MF (2013) Bacterially produced recombinant influenza vaccines based on virus-like particles. PLoS One, in press Impact: 3.8 190 Skibinski DA, Hanson BJ, Lin Y, von Messling V, Jegerlehner A, Tee JB, Chye de H, Wong SK, Ng AA, Lee HY, Au B, Lee BT, Santoso L, Poidinger M, Fairhurst AM, Matter A, Bachmann MF, Saudan P, Connolly JE. (2013). Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine. PLoS One 18;8(10):e76571. doi: 10.1371/journal.pone.0076571. eCollection 2013. 191 Zabel F, Mohanan D, Bessa J, Link A, Fettelschoss A, Saudan P, Kündig TM, Bachmann MF. (2014) Viral particles drive rapid differentiation of memory B cells into secondary plasma cells producing increased levels of antibodies. J Immunol. 192(12):5499-508. 192 Uermösi C, Zabel F, Manolova V, Bauer M, Beerli RR, Senti G, Kündig TM, Saudan P, Bachmann MF (2014) IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. Allergy. 69(3):338-47.

30

193 Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, SchwarzK, Johansen P, Jennings GT, Bachmann MF (2014) Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type II diabetesMolecular Therapy – Methods & Clinical Development, in press 194 Dallenbach K, Maurer P, Röhn T, Kopf M, Bachmann MF (2014) Protective effect of a germline antibody in inflammatory autoimmune disease. EJI, in press 195 Low JG, Lee LS, Ooi EE, Ethirajulu K, Yeo P, Matter A, Connolly JE, Skibinski DA, Saudan P, Bachmann MF, Hanson BJ, Lu Q, Maurer-Stroh S, Lim S, Novotny-Diermayr V. (2014) Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine. 32:5041-8

Total Impact Factor: 1530.6 Reviews and Commentaries: 1. Bachmann, M.F., and T.M. Kundig. 1994. In vivo versus in vitro assays for assessment of T- and B- cell function. Curr Opin Immunol 6:320-326. Impact: 8.7 2. Kundig, T.M., M.F. Bachmann, P.S. Ohashi, H. Pircher, H. Hengartner, and R.M. Zinkernagel. 1996. On T cell memory: arguments for antigen dependence. Immunol Rev 150:63-90. Impact: 12.1 3. Zinkernagel, R.M., M.F. Bachmann, T.M. Kundig, S. Oehen, H. Pirchet, and H. Hengartner. 1996. On immunological memory. Annu Rev Immunol 14:333-367. Impact: 37.6 4. Aichele, P., M.F. Bachmann, H. Hengartner, and R.M. Zinkernagel. 1996. Immunopathology or organ-specific autoimmunity as a consequence of virus infection. Immunol Rev 152:21-45. Impact: 12.1

31

5. Bachmann, M.F., and R.M. Zinkernagel. 1996. The influence of virus structure on antibody responses and virus serotype formation. Immunol Today 17:553-558. Impact: 9.5 6. Bachmann, M.F., and R.M. Zinkernagel. 1997. Neutralizing antiviral B cell responses. Annu Rev Immunol 15:235-270. Impact: 37.6 7. Bachmann, M.F. 1998. The role of germinal centers for antiviral B cell responses. Immunol Res 17:329-344. Impact: 3 8. Bachmann, M.F., R.M. Zinkernagel, and A. Oxenius. 1998. Immune responses in the absence of costimulation: viruses know the trick. J Immunol 161:5791-5794. Impact: 5.5 9. Sebzda, E., S. Mariathasan, T. Ohteki, R. Jones, M.F. Bachmann, and P.S. Ohashi. 1999. Selection of the T cell repertoire. Annu Rev Immunol 17:829-874. Impact: 37.6 10. Bachmann, M.F., and M. Kopf. 1999. The role of B cells in acute and chronic infections. Curr Opin Immunol 11:332-339. Impact: 8.7 11. Bachmann, M.F., and P.S. Ohashi. 1999. The role of T-cell receptor dimerization in T-cell activation. Immunol Today 20:568-576. Impact: 9.5 12. A number of small commentaries on different paper: Bachmann, M.F. 2000. Developmentally regulated TCR efficiency. Immunology Today 21:529. Bachmann, M.F. 2001. ICOS: signal 2 in the periphery. Trends Immunol 22:124. Bachmann, M.F. 2001. Complements for mad-cow disease. Trends Immunol 22:297. Bachmann, M.F. 2001. Blocking lymphotoxin: a potential therapy for diabetes? Trends Immunol 22:420. Bachmann, M.F. 2001. TREM-2: a novel link between dendritic cell maturation and T-cell priming. Trends Immunol 23:10. Bachmann, M.F. 2002. Vaccination against Alzheimer`s disease: hope renewed. Trends Immunol 23:569. 13. Bachmann, M.F., and G.T. Jennings. 2001. Challenges and new approaches for the vaccine industry. Drug Discov Today 6:566-568. Impact: 6.9

32

14. Bachmann, M.F., and M. Kopf. 2001. On the role of the innate immunity in autoimmune disease. J Exp Med 193:F47-50. Impact: 13.2 15. Zinkernagel, R.M., A. LaMarre, A. Ciurea, L. Hunziker, A.F. Ochsenbein, K.D. McCoy, T. Fehr, M.F. Bachmann, U. Kalinke, and H. Hengartner. 2001. Neutralizing antiviral antibody responses. Adv Immunol 79:1-53. Impact: 7.2 16. Lechner, F., A. Jegerlehner, A.C. Tissot, P. Maurer, P. Sebbel, W.A. Renner, G.T. Jennings, and M.F. Bachmann. 2003. Virus-like particles as a modular system for novel vaccines. Intervirology 45:212-217. Impact: 1.9 17. Bachmann, M.F., and M. Kopf. 2002. Balancing protective immunity and immunopathology. Curr Opin Immunol 14:413-419. Impact: 8.7 18. Jennings, G.T., and M.F. Bachmann. 2002. Immunotherapies: cause for measured optimism. Drug Discov Today 7:994-996. Impact: 5.9 19. Spohn, G., and M.F. Bachmann. 2003. Therapeutic vaccination to block receptor-ligand interactions. Expert Opin Biol Ther 3:469-476. Impact: 3.3 20. Bachmann, M.F., and M.R. Dyer. 2004. Therapeutic vaccination for chronic diseases: A new class of drugs in sight. Nat Rev Drug Discov 3:1-8. Impact: 33.1 21. Gatto, D., and M.F. Bachmann. 2005. Function of marginal zone B cells i antiviral B-cell responses. Crit Rev Immunol 25:331-342. Impact: 3.9 22 Bachmann, M.F., M. Kopf, and B.J. Marsland. 2006. Chemokines: More than just road signs. Nat Rev Immunol 6:159-164. Impact: 33.1 23 Bachmann, M.F., J. Nussberger, A.C. Tissot, and G.T. Jennings. 2006. Reply to 'Blood pressure vaccine shot down by safety concerns'. Nat Med 12:270. Impact: 22.8 24 Maurer, P., and M.F. Bachmann. 2006. Therapeutic vaccines for nicotine dependence. Curr Opin Mol Ther 8:11-16. Impact: 3.1

33

25 Dyer M.R., W.A. Renner and M F. Bachmann. 2006. A second vaccine revolution for the new epidemics of the 21st century. Drug Discovery Today 11:1028-1033 Impact: 6.9 26 Jennings G.T. and M.F. Bachmann. 2007. Designing Recombinant Vaccines with Viral Properties: A Rational Approach to More Effective Vaccines. Curr Mol Med 2007 Mar 7:143-55. Impact: 4.5 27 Spohn G. and M.F. Bachmann 2007. Targeting osteoporosis and rheumatoid arthritis by active vaccination against RANKL. Adv Exp Med Biol. 2007;602:135-42. Impact: 1.8 28 Maurer P. and M.F. Bachmann 2007. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs. 16:1775-83. 34 Impact: 4.7 Bachmann M. F. and A. Oxenius 2007. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep. 8:1142-8. Impact: 9.8 34 Hinton H.J., Jegerlehner A., and M.F. Bachmann 2008. Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors. Curr Top Microbiol Immunol. 319:1-15. Impact: 4.9 35 Jennings, G.T., and M.F. Bachmann. 2008. The coming of age of virus-like particle vaccines. Biological chemistry 389:521-536. Impact: 2.7 36 Spohn, G., and M.F. Bachmann. 2008. Exploiting viral properties for the rational design of modern vaccines. Expert review of vaccines 7:43-54. Impact: 4.2 37 Jennings, G.T., and M.F. Bachmann. 2009. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annual review of pharmacology and toxicology 49:303-326 Impact: 21.5 38 Maurer, P., and M.F. Bachmann. 2009. Immunization against angiotensins for the treatment of hypertension. Clinical immunology (Orlando, Fla 134:89-95.) Impact: 3.6 39 Bachmann, M.F., and G.T. Jennings. 2010. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nature reviews Immunology 10:787-796.

34

Impact: 33.1 40 Kundig, T.M., and M.F. Bachmann. 2010. Allergen-specific immunotherapy: regulatory T cells or allergen-specific IgG? Human vaccines 6:673-675. Impact: 3.1 41 Link, A., and M.F. Bachmann. 2010. Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines. Immunotherapy 2:561-574. Impact: 2.4 42 Rohn, T.A., and M.F. Bachmann. 2010. Vaccines against non-communicable diseases. Current opinion in immunology 22:391-396. Impact: 8.7 43 Bessa, J., and M.F. Bachmann. 2010. T cell-dependent and -independent IgA responses: role of TLR signalling. Immunological investigations 39:407-428. Impact: 1.5 44 Kopf, M., M.F. Bachmann, and B.J. Marsland. 2010. Averting inflammation by targeting the cytokine environment. Nature reviews Drug Discovery 9:703-718. Impact: 33.1 45 Bachmann MF, Jennings GT. (2011) Therapeutic vaccines for chronic diseases: successes and technical challenges. Philos Trans R Soc Lond B Biol Sci. 366: 2815-22. Impact: 6.1 46 Rebeaud F and Bachmann MF. (2012). Immunization strategies for Clostridium difficile infections. Expert Rev Vaccines 11:469-79. Impact: 4.2 47 Bachmann MF. (2012) Taurine: Energy drink for T cells. Eur J Immunol. 42: 819-21. Impact: 5 48 Bachmann MF, Whitehead P. (2013) Active immunotherapy for chronic diseases. Vaccine. 31:1777-84 Impact: 3.5 49 Reyes-Sandoval A, Bachmann MF. (2013) Plasmodium vivax malaria vaccines: Why are we where we are? Hum Vaccin Immunother. 9:. Impact: 3.1 50 Zabel F., Kündig, TM and Bachmann MF. (2013) Virus-induced humoral immunity: on how B cell responses are initiated. Curr Opin Virol. 2013 3:357-62. Impact: 2.5

35

51 Bachmann MF, Whitehead P. (2013) Active immunotherapy for chronic diseases. Vaccine. 31:1777-84. Impact: 3.5 52 Klimek L, Bachmann MF, Senti G, Kündig TM (2014). Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. Expert Rev Clin Immunol. 10(8):1059-67. 53 Fettelschoss A, Zabel F, Bachmann MF. (2014) Vaccination against Alzheimer disease: an update on future strategies. Hum Vaccin Immunother. 10(4):847-51. 54 Kündig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. (2014) Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014 Mar;133(3):930-1. Total Impact Factor Reviews: 464.1 Grand Total: 1994.7 Book Chapters: Bachmann, M.F. (1997). Evaluation of lymphocytic choriomeningitis virus specific CTL responses. In Lefkowitz, Immunological Methods, Academic press, 1919-1933 Bachmann, M.F. (1997). Evaluation of vaccinia virus specific CTL responses. In Lefkowitz, Immunological Methods, Academic press, 1910-1917 Bachmann, M.F. (1997). Evaluation of vesicular stomatitis virus specific CTL responses. In Lefkowitz, Immunological Methods, Academic Press, 1897-1907 Bachmann, M.F. (2001). Antigens: Thymus-dependent. In Encyclopedia of Life Sciences, Macmillan Ltd., published on-line: www.els.net L.T. Nguyen, Bachmann, M.F. and Ohashi, P. (2002) Contribution of LCMV transgenic models to understanding of T lymphocyte development, activation, tolerance and autoimmunity. Arenaviruses II, Springer-Verlag Berlin, 119-144 Bachmann, M.F. and Jennings, G. (2004). Virus-like particles: Combining Innate and Adaptive Immunity for Effective Vaccination. Novel Vaccination Strategies, Wiley-VCH Bachmann, M.F. and Kündig, T.M. (2005). Immune Defence, Cell Mediated. Meyers, Encyclopedia of Molecular Cell Biology and Molecular Medicine, Wiley-VCH Bachmann, M.F. and Oxenius, A.O. (2005). Stimulation of antigen presenting cells: from classical adjuvants to Toll-like receptor (TLR) ligands. Antigen presenting cells, Wiley-VCH

36

Stephan Martin and M.F. Bachmann (2005). Immunopotentiators in non-infectious disease vaccines. Immunopotentiations, Wiley-VCH S.W. Martin and M.F. Bachmann (2006). Vaccination to treat noninfectious diseases: surveying the opportunities. Immunopotentiators in modern vaccines. Academic Press (AP). M.F. Bachmann and T.M. Künding (2007). Cell mediated immune defense. Meyers Immunology, Wiley-VCH T.A. Röhn and M.F. Bachmann (2009). Tuning the immune system to our advantage: design of vaccines with tailored functions. Medicinal Protein Engineering. CRC Press G. Lipowsky and M.F. Bachmann (2011). Design and development of recombinant vaccines with viral properties. Development of vaccines., Wiley-VCH

37

List of Patents/Patent Applicants (Until 2010) P1003PC00 Wolfgang A. Renner, Frank Hennecke, Lars Nieba, Martin Bachmann “Ordered Molecular Presentation of Antigens, Method of Preparation” PCT Patent Application published on 08.06.2000 as WO 00/32227A2. P1008PC00 Wolfgang A. Renner, Frank Hennecke, Lars Nieba, Peter Sebbel, Nicolas Dunant, Martin Bachmann, Alain Tissot, Franziska Lechner "Molecular Antigen Array" PCT Patent Application published on 15.11.2001 as WO 01/85208A2. PA018WO Martin Bachmann, Wolfgang A. Renner „Compositions for Inducing Self-Specific Anti-IgE and Uses Thereof“ PCT Patent Application published on 07.02.02 as WO02/09751A2. P1009PC00 Martin Bachmann, Tazio Storni "In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses induced by Virus Like Particles". PCT Patent Application published on 27.03.2003 as WO 03/024480A2. P1010PC00 Martin Bachmann, Tazio Storni, Patrik Maurer, Alain Tissot, Katrin Schwarz, Edwin Meijerink, Gerd Lipowsky, Paul Pumpens, Indulis Cielens, Regina Renhofa "Packaging of ISS into Virus-Like Particles: Method of Preparation and Use". PCT Patent Application published on 27.03.2003 as WO 03/024481A2. P1011PC00 Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek "Molecular Antigen Array" PCT Patent Application published on 25.07.2002 as WO2002/056905A2.

38

P1012PC00 Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Lüönd, Matthias Staufenbiel, Peter Frey "Molecular Antigen Array". PCT Patent Application published on 25.07.2002 as WO2002/056907A2 . P1014PC00 Martin Bachmann, Wolfgang A. Renner "Packaged Virus-Like Particles for Use as Adjuvants: Method of Preparation and Use" PCT-Patent Application published on 31.12.2003 as WO2004/000351A1. P1015PC00 Martin Bachmann, Patrik Maurer "Hapten-Carrier Conjugates and Uses Thereof" PCT-Patent Application published on 29.01.2004 as WO2004/009116A2 as well as the corresponding US Patent US 6,932,971 P1016PC00 Martin Bachmann "Angiotensin Peptide-Carrier-Conjugates and Uses Thereof" PCT Patent Application published on 17.04.2003 as WO 03/031466A2 as well as the corresponding US Patent US 7,115,266 P1017PC00 Martin Bachmann, Gary Jennings, Ivo Sonderegger "Antigen Arrays for Treatment of Allergic Eosinophilic Diseases" PCT Patent Application published on 15.05.2003 as WO 03/040164 A2 as well as the corresponding US Patent US 7,094,409 P1018PC00 Martin Bachmann, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa "Molecular Antigen Arrays“ PCT-Patent Application published on 22.01.2004 as WO2004/007538A2 as well as the corresponding US Patent US 7,138, 252 P1019PC00 Lorenz Vogt, Martin Bachmann "T-Cell Modulatory Compounds and Methods"

39

PCT-Patent Application published on 18.03.2004 as WO2004/022594A2. P1020PC00 Wolfgang A. Renner, Martin Bachmann, Patrick Maurer, Erica Pellicioli "Prion Protein Carrier-Conjugates" PCT Patent Application published on 24.07.2003 as WO2003/059386A2. P1021PC00 Philippe Saudan, Frank Hennecke, Martin Bachmann, Dorothee Stern “Method for Protein Production“ PCT-Patent Application published on 24.06.2004 as WO2004/053137A2. P1022PC00 Dominique Gatto, Martin Bachmann „Selection of B Cells with Specificity of Interest. Method of Preparation and Use“ PCT-Patent Application published on 25.11.2004 as WO2004/102198A2. P1023PC00 Martin Bachmann, Patrik Maurer, Gunther Spohn "Antigen Arrays for Treatment of Bone Disease" PCT Patent Application published on 15.05.2003 as WO 03/039225A2 as well as the corresponding US Patent US 7,128,911 P1024PC00 Martin Bachmann, Alma Fulurija "Grehlin-Carrier Conjugates" PCT-Patent Application published on 29.01.2004 as WO2004/009124A2. P1025PC00 Martin Bachmann, Alain Tissot, Rainer Ortmann, Rainer Lüönd, Matthias Staufenbiel, Peter Frey "Amyloid β1-6 Antigen Arrays" PCT-Patent Application published on 26.02.2004 WO2004/016282A1. P1026PC00 Roger Beerli, Martin Bachmann "Polypeptides involved in cell-entry of the Adenoviruses of Subtype B" PCT-Patent Application published on 09.12.2004 as WO2004/106532A1.

40

P1027PC00 Philippe Saudan, Martin Bachmann " Methods and Compositions for Modulating the Interaction between Adiponectin and its Receptor " PCT-Patent Application published on 11.11.2004 as WO2004/096272A2. P1030PC00 Martin F. Bachmann, Vania Manolova, Tazio Storni "Enhancement of A-type CpG-Induced INFa-Production by Liposomes: Method of Preparation and Use" PCT-Patent Application published on 17.02.2005 as WO2005/014110A1. P1031PC00 Martin F. Bachmann, Katrin Schwarz "Packaged Virus-Like Particles " PCT-Patent Application published on 20.01.2005 as WO2005/004907A1. P1032PC00 Martin F. Bachmann, Patrik Maurer, Gunther Spohn “TNF-alpha-Carrier Conjugates” PCT-Patent Application published on 15.12.2005 as WO2005/117983A2. P1033PC00 Adrian Huber, Alain Tissot, Martin F. Bachmann “IL-23 P19 Antigen Array and Uses Thereof” PCT-Patent Application published on 17.11.2005 as WO2005/108425A1. P1034PC00 Martin F. Bachmann, Alma Fulurija “Ghrelin-Carrier Conjugates”. PCT-Patent Application published on 28.07.2005 as WO2005/068639A2 P1035PC00 Karl G. Proba, Patrik Maurer, Martin F. Bachmann, Edwin Meijerink, Katrin Schwarz “VLP-Antigen Conjugates and Their Use as Vaccines” PCT-Patent Application published on 13.04.2006 as WO2006/037787A2. P1036PC00

41

Martin F. Bachmann, Vania Manolova, Edwin Meijerink, Karl G Proba, Katrin Schwarz “Melan-A Peptide Analogue-Virus-Like-Particles Conjugates “. PCT-Patent Application published on 07.10.2004 as WO2004/085635A1. P1037PC00 Martin F. Bachmann, Adrian Huber, Vania Manolova, Edwin Meijerink, Karl G. Proba, Alain Tissot “HIV-Peptide-Carrier-Conjugates” PCT-Patent Application published on 07.10.2004 as WO2004/084939A2. P1038PC00 Martin F. Bachmann, Andreas Cornelius, Vania Manolova, Patrik Maurer, Edwin Meijerink, Karl G. Proba, Katrin Schwarz “Packaging of Immunostimulatory substances into Virus-Like Particles: Method of preparation and use” PCT-Patent Application published on 07.10.2004 as WO 2004/084940A1. P1039PC00 Martin F. Bachmann, Patrik Maurer, Yu Zou, Alain Tissot “IL-15 Antigen Arrays and Uses Thereof” PCT-Patent Application published on 22.06.2006 as WO2006/063974A2. P1040PC00 Martin F. Bachmann, Patrik Maurer, Gunther Spohn “Medical Uses of Carrier Conjugates of Non-Human TNF-Peptides” PCT-Patent Application published on 15.12.2005 as WO2005/117963A1. P1041PC00 Martin F. Bachmann, Alma Fulurija, Gary Jennings, Edwin Meijerink “Carrier Conjugates of GnRH-Peptides” PCT-Patent Application published on 16.03.2006 as WO2006/027300A2. P1042PC00 Martin F. Bachmann, Alain Tissot, Gary Jennings, Regina Renhofa, Paul Pumpens, Indulis Cielens “Molecular Antigen Arrays” PCT-Patent Application published on 30.03.2006 as WO2006/032674A1. P1043PC00

42

Martin F. Bachmann, Philippe Saudan, Alma Fulurija “Gastric Inhibitory Polypeptide (GIP) Antigen Arrays and Uses Thereof” PCT-Patent Application published on 04.05.2006 as WO2006/045796A2. P1044PC00 Martin F. Bachmann, Philippe Saudan, Klaus Dietmeier, Alain Tissot “T-Cadherin and Uses Thereof” PCT-Patent Application published on 04.05.2006 as WO2006/045849A1. P1048PC00 Martin F. Bachmann, Stephan Utzinger, Klaus Dietmeier, Monika Bauer, Nicole Schmitz “Cat Allergen Conjugates and Uses Thereof” PCT-Patent Application published on 21.09.2006 as WO2006/097530A2. PCT/EP2006/063198 Martin F Bachmann, Alain Tissot, Andrea Jegerlehner, Philippe Saudan, Yu Zou, Nicole Schlitz, Adrian Huber, Stephen Martin, Heather Hinton „Antigen Conjugates and used thereoff“ WO2006/134125A1 PCT/EP2006/066526 Martin Bachmann, Philippe Saudan, Andrea Jegerlehner, Till Röhn, Gary Jennings “HIV Peptide conjugates and uses thereoff” WO2007/039458A2 PCT/EP2006/066866 Martin Bachmann, Gunther Sohn, Alain Tissot “Interleukin 1 conjugates and uses thereof” WO/2007/039552 PCT/EP2006/069734 Wolfgang Renner, Martin Bachmann et al. „Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity“ WO2007/068747A1 PCT/EP2007/053007 Martin Bachmann, Gunther Spohn, Alain Tissot „Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases“ WO2008/037504A1

43

PCT/EP2007/061570 Martin Bachmann, Roger Beerli, Monika Bauer „Selection of Human Monoclonal Antibodies by Mammalian Cell Display“ WO2008/055795A1 PCT/EP2007/064522 Adrian Huber, Martin Bachmann et al. „Circular CCR5 Peptide Conjugates and Uses Thereof“ WO/2008/074895 PCT/EP2008/054775 Martin Bachmann, Patrik Maurer, Philipp Müller, Thomas Pfister, Wolfgang Renner “Vaccination Regimen for B-Cell Vaccines” WO2008/129020A PCT/EP2008/062104 Martin Bachmann, Monika Bauer, Roger Beerli, Patrik Maurer “Human monoclonal Nicotine specific Antibodies” WO2009/068335A1 PCT/EP2008/068209 Martin Bachmann, Gary Jennings Till Röhn „Nerve Growth Factor Conjugates and Uses thereof” WO2009/080823A2 PCT/EP2009/052639 Martin Bachmann, Gunther Spohn “Use of Interleukin-1 Conjugates in the Treatment of Diabetes” WO2009/109643A2

44